John C. Pepia Sells 3,000 Shares of Mednax, Inc (MD) Stock
Mednax, Inc (NYSE:MD) insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Mednax, Inc (MD) traded down $0.10 on Thursday, reaching $51.58. The company’s stock had a trading volume of 1,146,300 shares, compared to its average volume of 1,093,425. Mednax, Inc has a 52 week low of $40.56 and a 52 week high of $72.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $4,840.10, a price-to-earnings ratio of 15.80, a PEG ratio of 1.67 and a beta of 0.40.
Mednax (NYSE:MD) last posted its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. research analysts predict that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.
Several research firms recently weighed in on MD. Piper Jaffray Companies initiated coverage on Mednax in a report on Wednesday. They issued an “overweight” rating and a $58.00 price objective for the company. Jefferies Group reiterated a “hold” rating and issued a $46.00 target price on shares of Mednax in a research note on Tuesday, October 3rd. Citigroup cut their target price on Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Robert W. Baird lifted their target price on Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $53.70.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/14/john-c-pepia-sells-3000-shares-of-mednax-inc-md-stock.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Stock Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related stocks with our FREE daily email newsletter.